Common risks shared with all GLP-1 medications include gastrointestinal side effects - nausea, vomiting, diarrhea, constipation - especially when starting or increasing dose
In the STEP 1 trial, participants lost an average of 14.9% of body weight over 68 weeks
Recombinant human erythropoietins: very rare risk of severe cutaneous adverse reactions (SCARs)
Just how much of a challenge this posed can be gauged from the fact that Mutt's group needed 10km of porcine small intestine to obtain about 1mg of pure secretin (Rehfeld 2012)
Lixisenatide, a structurally modified derivative of exendin-4, addresses some of these limitations by offering a longer half-life of approximately 3 h, thereby permitting once-daily dosing (Leon et al., 2017)
The New Question Every Pipeline Must Answer The strategic question has changed